• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

由SGLT-2抑制剂使用、心包炎和禁食引发的正常血糖性糖尿病酮症酸中毒:一例报告

Euglycemic Diabetic Ketoacidosis Precipitated by SGLT-2 Inhibitor Use, Pericarditis, and Fasting: A Case Report.

作者信息

Mendelsohn Rebecca A, Taveras Anabelle N, Mazer Benjamin A, Clayton Lisa M

机构信息

Florida Atlantic University Charles E. Schmidt College of Medicine, Department of Emergency Medicine, Boca Raton, Florida.

出版信息

Clin Pract Cases Emerg Med. 2020 Aug;4(3):389-392. doi: 10.5811/cpcem.2020.4.46056.

DOI:10.5811/cpcem.2020.4.46056
PMID:32926693
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7434240/
Abstract

INTRODUCTION

Diabetic ketoacidosis (DKA) is a potentially life-threatening complication of diabetes mellitus. Less prevalent is euglycemic DKA (eDKA)-DKA with serum glucose less than 200 mg/dL; however, it is increasing in frequency with the introduction of sodium glucose cotransporter 2 (SGLT-2) inhibitors for treatment of type 2 diabetes.

CASE REPORT

We report a case of SGLT-2 inhibitor-associated eDKA presenting with concurrent acute pericarditis.

DISCUSSION

Our case suggests that the cause of eDKA can be multifactorial when decreased oral intake occurs in the setting of an acute cause of physiologic stress.

CONCLUSION

Prompt recognition of eDKA in the emergency department may allow earlier diagnosis and treatment directed at one or more of its underlying causes.

摘要

引言

糖尿病酮症酸中毒(DKA)是糖尿病一种潜在的危及生命的并发症。血糖正常的DKA(eDKA)——血清葡萄糖低于200mg/dL的DKA——相对少见;然而,随着用于治疗2型糖尿病的钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂的引入,其发生率正在增加。

病例报告

我们报告1例与SGLT-2抑制剂相关的eDKA病例,该病例同时伴有急性心包炎。

讨论

我们的病例表明,当在急性生理应激情况下口服摄入量减少时,eDKA的病因可能是多因素的。

结论

在急诊科及时识别eDKA可能有助于更早诊断并针对其一种或多种潜在病因进行治疗。

相似文献

1
Euglycemic Diabetic Ketoacidosis Precipitated by SGLT-2 Inhibitor Use, Pericarditis, and Fasting: A Case Report.由SGLT-2抑制剂使用、心包炎和禁食引发的正常血糖性糖尿病酮症酸中毒:一例报告
Clin Pract Cases Emerg Med. 2020 Aug;4(3):389-392. doi: 10.5811/cpcem.2020.4.46056.
2
Euglycemic Diabetic Ketoacidosis Induced by Sodium-Glucose Cotransporter-2 Inhibitor Use and Coronary Angiography: A Case Report.钠-葡萄糖协同转运蛋白2抑制剂使用与冠状动脉造影诱发的正常血糖性糖尿病酮症酸中毒:一例报告
Cureus. 2024 Jan 11;16(1):e52122. doi: 10.7759/cureus.52122. eCollection 2024 Jan.
3
From Sweet to Sour: SGLT-2-Inhibitor-Induced Euglycemic Diabetic Ketoacidosis.从甜蜜到酸涩:钠-葡萄糖协同转运蛋白2抑制剂诱发的正常血糖性糖尿病酮症酸中毒
J Pers Med. 2024 Jun 21;14(7):665. doi: 10.3390/jpm14070665.
4
Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis.正常血糖性糖尿病酮症酸中毒机制的新观点
Int J Endocrinol. 2018 Oct 2;2018:7074868. doi: 10.1155/2018/7074868. eCollection 2018.
5
Euglycemic diabetic ketoacidosis induced by sodium-glucose cotransporter 2 inhibitor in the setting of prolonged fasting: a case report.钠-葡萄糖共转运蛋白 2 抑制剂引起的空腹延长后血糖正常的糖尿病酮症酸中毒:病例报告。
J Med Case Rep. 2022 Mar 29;16(1):138. doi: 10.1186/s13256-022-03347-1.
6
Sodium-glucose Cotransporter-2 Inhibitors induced euglycemic diabetic ketoacidosis: A meta summary of case reports.钠-葡萄糖协同转运蛋白2抑制剂诱发的正常血糖性糖尿病酮症酸中毒:病例报告的Meta综述
World J Diabetes. 2023 Aug 15;14(8):1314-1322. doi: 10.4239/wjd.v14.i8.1314.
7
An Unsuspected Case of Euglycemic Diabetic Ketoacidosis With Twists.一例伴有波折的隐匿性正常血糖性糖尿病酮症酸中毒病例。
Cureus. 2022 Apr 10;14(4):e24016. doi: 10.7759/cureus.24016. eCollection 2022 Apr.
8
Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.与钠-葡萄糖协同转运蛋白2抑制剂使用相关的正常血糖性糖尿病酮症酸中毒:一例病例报告及文献综述
Int J Emerg Med. 2019 Sep 5;12(1):27. doi: 10.1186/s12245-019-0240-0.
9
Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors.SGLT-2 抑制剂时代的血糖正常的糖尿病酮症酸中毒。
BMJ Open Diabetes Res Care. 2023 Oct;11(5). doi: 10.1136/bmjdrc-2023-003666.
10
Euglycemic diabetic ketoacidosis caused by dapagliflozin: A case report.达格列净所致正常血糖性糖尿病酮症酸中毒:一例报告
Medicine (Baltimore). 2018 Jun;97(25):e11056. doi: 10.1097/MD.0000000000011056.

引用本文的文献

1
Euglycemic Diabetic Ketoacidosis: Experience with 44 Patients and Comparison to Hyperglycemic Diabetic Ketoacidosis.血糖正常的糖尿病酮症酸中毒:44 例患者的经验及与高血糖的糖尿病酮症酸中毒的比较。
West J Emerg Med. 2023 Nov;24(6):1049-1055. doi: 10.5811/westjem.60361.
2
Euglycemic diabetic ketoacidosis induced by sodium-glucose cotransporter 2 inhibitor in the setting of prolonged fasting: a case report.钠-葡萄糖共转运蛋白 2 抑制剂引起的空腹延长后血糖正常的糖尿病酮症酸中毒:病例报告。
J Med Case Rep. 2022 Mar 29;16(1):138. doi: 10.1186/s13256-022-03347-1.
3
Postoperative Euglycemic Ketoacidosis in Type 2 Diabetes Associated with Sodium-Glucose Cotransporter 2 Inhibitor: Insights Into Pathogenesis and Management Strategy.2型糖尿病患者使用钠-葡萄糖协同转运蛋白2抑制剂后出现的术后正常血糖性酮症酸中毒:发病机制及管理策略的见解
Cureus. 2021 Jun 8;13(6):e15533. doi: 10.7759/cureus.15533.
4
SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort.在一个多中心队列中,SGLT-2 抑制剂与血糖正常和高血糖性 DKA 相关。
Sci Rep. 2021 May 13;11(1):10293. doi: 10.1038/s41598-021-89752-w.

本文引用的文献

1
Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review.与钠-葡萄糖共转运蛋白 2 抑制剂相关的围手术期糖尿病酮症酸中毒:系统评价。
Br J Anaesth. 2019 Jul;123(1):27-36. doi: 10.1016/j.bja.2019.03.028. Epub 2019 May 3.
2
Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis.正常血糖性糖尿病酮症酸中毒机制的新观点
Int J Endocrinol. 2018 Oct 2;2018:7074868. doi: 10.1155/2018/7074868. eCollection 2018.
3
Euglycemic diabetic ketoacidosis caused by dapagliflozin: A case report.达格列净所致正常血糖性糖尿病酮症酸中毒:一例报告
Medicine (Baltimore). 2018 Jun;97(25):e11056. doi: 10.1097/MD.0000000000011056.
4
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).卡格列净用于心血管事件的一级和二级预防:来自 CANVAS 项目(卡格列净心血管评估研究)的结果。
Circulation. 2018 Jan 23;137(4):323-334. doi: 10.1161/CIRCULATIONAHA.117.032038. Epub 2017 Nov 13.
5
SGLT2 Inhibitors and the Diabetic Kidney.钠-葡萄糖协同转运蛋白 2 抑制剂与糖尿病肾脏疾病
Diabetes Care. 2016 Aug;39 Suppl 2:S165-71. doi: 10.2337/dcS15-3006.
6
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.恩格列净与 2 型糖尿病患者的肾脏疾病进展。
N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.
7
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.恩格列净:在 2 型糖尿病中的心血管结局和死亡率。
N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
8
Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors.正常血糖性糖尿病酮症酸中毒:SGLT2抑制剂相关的可预测、可检测且可预防的安全问题
Diabetes Care. 2015 Sep;38(9):1638-42. doi: 10.2337/dc15-1380.
9
Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.正常血糖性糖尿病酮症酸中毒:钠-葡萄糖协同转运蛋白2抑制剂治疗的一种潜在并发症。
Diabetes Care. 2015 Sep;38(9):1687-93. doi: 10.2337/dc15-0843. Epub 2015 Jun 15.
10
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.用达格列净抑制胰岛α细胞中的葡萄糖转运蛋白 SGLT2 可触发胰高血糖素的分泌。
Nat Med. 2015 May;21(5):512-7. doi: 10.1038/nm.3828. Epub 2015 Apr 20.